nodes	percent_of_prediction	percent_of_DWPC	metapath
Clenbuterol—NGF—trigeminal nerve—meningioma	0.839	0.842	CbGeAlD
Clenbuterol—NGF—spinal cord—meningioma	0.0817	0.0821	CbGeAlD
Clenbuterol—NGF—brain—meningioma	0.0526	0.0529	CbGeAlD
Clenbuterol—ADRB1—brain—meningioma	0.0137	0.0138	CbGeAlD
Clenbuterol—CYP1A1—brain—meningioma	0.00884	0.00888	CbGeAlD
Clenbuterol—TNF—Cellular roles of Anthrax toxin—PGR—meningioma	0.00031	0.0668	CbGpPWpGaD
Clenbuterol—TNF—Amyotrophic lateral sclerosis (ALS)—CST3—meningioma	0.000233	0.0501	CbGpPWpGaD
Clenbuterol—NGF—SHP2 signaling—PDGFB—meningioma	0.000229	0.0494	CbGpPWpGaD
Clenbuterol—TNF—amb2 Integrin signaling—PLAUR—meningioma	0.000186	0.04	CbGpPWpGaD
Clenbuterol—NGF—PI3K/AKT activation—PDGFB—meningioma	0.000147	0.0317	CbGpPWpGaD
Clenbuterol—ADRB3—G alpha (s) signalling events—TSHB—meningioma	0.000136	0.0292	CbGpPWpGaD
Clenbuterol—TNF—amb2 Integrin signaling—PLAU—meningioma	0.00013	0.0281	CbGpPWpGaD
Clenbuterol—NGF—SIDS Susceptibility Pathways—HES1—meningioma	0.000121	0.0262	CbGpPWpGaD
Clenbuterol—TNF—Aryl Hydrocarbon Receptor Pathway—HES1—meningioma	0.000118	0.0253	CbGpPWpGaD
Clenbuterol—NGF—Trk receptor signaling mediated by PI3K and PLC-gamma—AKT1—meningioma	0.000111	0.0238	CbGpPWpGaD
Clenbuterol—NGF—PI3K/AKT activation—ERBB2—meningioma	9.86e-05	0.0212	CbGpPWpGaD
Clenbuterol—NGF—MAPK Signaling Pathway—PDGFB—meningioma	9.79e-05	0.0211	CbGpPWpGaD
Clenbuterol—ADRB2—GPCRs, Other—SMO—meningioma	8.57e-05	0.0185	CbGpPWpGaD
Clenbuterol—NGF—PI3K/AKT activation—PTEN—meningioma	8.41e-05	0.0181	CbGpPWpGaD
Clenbuterol—NGF—NGF signalling via TRKA from the plasma membrane—PDGFB—meningioma	8.32e-05	0.0179	CbGpPWpGaD
Clenbuterol—ADRB1—G alpha (s) signalling events—TSHB—meningioma	8.04e-05	0.0173	CbGpPWpGaD
Clenbuterol—ADRB2—G alpha (s) signalling events—TSHB—meningioma	7.87e-05	0.017	CbGpPWpGaD
Clenbuterol—NGF—p75(NTR)-mediated signaling—TP53—meningioma	7.78e-05	0.0168	CbGpPWpGaD
Clenbuterol—NGF—p75(NTR)-mediated signaling—AKT1—meningioma	6.57e-05	0.0142	CbGpPWpGaD
Clenbuterol—ADRB3—Class A/1 (Rhodopsin-like receptors)—TSHB—meningioma	6.46e-05	0.0139	CbGpPWpGaD
Clenbuterol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—HES1—meningioma	6.45e-05	0.0139	CbGpPWpGaD
Clenbuterol—NGF—Signaling by NGF—PDGFB—meningioma	6.4e-05	0.0138	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—CST3—meningioma	6.39e-05	0.0138	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—SMO—meningioma	5.74e-05	0.0124	CbGpPWpGaD
Clenbuterol—NGF—NGF signalling via TRKA from the plasma membrane—ERBB2—meningioma	5.58e-05	0.012	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—TSHB—meningioma	4.92e-05	0.0106	CbGpPWpGaD
Clenbuterol—NGF—PI3K/AKT activation—AKT1—meningioma	4.85e-05	0.0104	CbGpPWpGaD
Clenbuterol—NGF—NGF signalling via TRKA from the plasma membrane—PTEN—meningioma	4.75e-05	0.0102	CbGpPWpGaD
Clenbuterol—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—meningioma	4.57e-05	0.00984	CbGpPWpGaD
Clenbuterol—TNF—SIDS Susceptibility Pathways—HES1—meningioma	4.42e-05	0.00953	CbGpPWpGaD
Clenbuterol—NGF—Signaling by NGF—ERBB2—meningioma	4.29e-05	0.00924	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR ligand binding—SMO—meningioma	4.18e-05	0.00901	CbGpPWpGaD
Clenbuterol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—meningioma	4.11e-05	0.00886	CbGpPWpGaD
Clenbuterol—ADRB1—Class A/1 (Rhodopsin-like receptors)—TSHB—meningioma	3.83e-05	0.00826	CbGpPWpGaD
Clenbuterol—NGF—MAPK Signaling Pathway—TP53—meningioma	3.82e-05	0.00823	CbGpPWpGaD
Clenbuterol—ADRB2—Class A/1 (Rhodopsin-like receptors)—TSHB—meningioma	3.75e-05	0.00808	CbGpPWpGaD
Clenbuterol—NGF—Signaling by NGF—PTEN—meningioma	3.66e-05	0.00788	CbGpPWpGaD
Clenbuterol—NGF—BDNF signaling pathway—AKT1—meningioma	3.65e-05	0.00786	CbGpPWpGaD
Clenbuterol—TNF—MAPK Signaling Pathway—PDGFB—meningioma	3.57e-05	0.00768	CbGpPWpGaD
Clenbuterol—TNF—TWEAK Signaling Pathway—AKT1—meningioma	3.56e-05	0.00767	CbGpPWpGaD
Clenbuterol—NGF—MAPK Signaling Pathway—AKT1—meningioma	3.23e-05	0.00695	CbGpPWpGaD
Clenbuterol—TNF—Ceramide signaling pathway—AKT1—meningioma	3.2e-05	0.00689	CbGpPWpGaD
Clenbuterol—TNF—Angiopoietin receptor Tie2-mediated signaling—AKT1—meningioma	3.1e-05	0.00667	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—AKT1—meningioma	2.96e-05	0.00637	CbGpPWpGaD
Clenbuterol—TNF—Folate Metabolism—TP53—meningioma	2.94e-05	0.00633	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—TSHB—meningioma	2.92e-05	0.00629	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—TSHB—meningioma	2.88e-05	0.00621	CbGpPWpGaD
Clenbuterol—TNF—Cardiac Hypertrophic Response—AKT1—meningioma	2.87e-05	0.00618	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—TSHB—meningioma	2.86e-05	0.00616	CbGpPWpGaD
Clenbuterol—TNF—Caspase Cascade in Apoptosis—AKT1—meningioma	2.79e-05	0.00601	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—TSHB—meningioma	2.78e-05	0.00599	CbGpPWpGaD
Clenbuterol—NGF—NGF signalling via TRKA from the plasma membrane—AKT1—meningioma	2.74e-05	0.0059	CbGpPWpGaD
Clenbuterol—TNF—Alzheimers Disease—TP53—meningioma	2.54e-05	0.00548	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—TSHB—meningioma	2.52e-05	0.00544	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR ligand binding—SMO—meningioma	2.48e-05	0.00535	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—SMO—meningioma	2.45e-05	0.00528	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR ligand binding—SMO—meningioma	2.43e-05	0.00523	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—TP53—meningioma	2.42e-05	0.00522	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—PGR—meningioma	2.35e-05	0.00506	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—ERBB2—meningioma	2.16e-05	0.00465	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—SMO—meningioma	2.15e-05	0.00463	CbGpPWpGaD
Clenbuterol—NGF—Signaling by NGF—AKT1—meningioma	2.11e-05	0.00454	CbGpPWpGaD
Clenbuterol—TNF—MicroRNAs in cardiomyocyte hypertrophy—AKT1—meningioma	2.04e-05	0.00441	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—AKT1—meningioma	2.04e-05	0.00441	CbGpPWpGaD
Clenbuterol—TNF—TNF alpha Signaling Pathway—AKT1—meningioma	1.9e-05	0.0041	CbGpPWpGaD
Clenbuterol—TNF—Spinal Cord Injury—TP53—meningioma	1.84e-05	0.00398	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—PTEN—meningioma	1.84e-05	0.00396	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—HES1—meningioma	1.76e-05	0.00379	CbGpPWpGaD
Clenbuterol—TNF—Toll-like Receptor Signaling Pathway—AKT1—meningioma	1.75e-05	0.00377	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—TSHB—meningioma	1.65e-05	0.00356	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—TSHB—meningioma	1.61e-05	0.00348	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—HES1—meningioma	1.61e-05	0.00346	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—TSHB—meningioma	1.5e-05	0.00323	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—TSHB—meningioma	1.49e-05	0.00321	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—TP53—meningioma	1.48e-05	0.0032	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—TSHB—meningioma	1.47e-05	0.00316	CbGpPWpGaD
Clenbuterol—TNF—MAPK Signaling Pathway—TP53—meningioma	1.39e-05	0.003	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—PDGFB—meningioma	1.37e-05	0.00296	CbGpPWpGaD
Clenbuterol—TNF—Regulation of toll-like receptor signaling pathway—AKT1—meningioma	1.37e-05	0.00295	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—SMO—meningioma	1.27e-05	0.00275	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—SMO—meningioma	1.27e-05	0.00273	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—TP53—meningioma	1.26e-05	0.0027	CbGpPWpGaD
Clenbuterol—TNF—Apoptosis—AKT1—meningioma	1.25e-05	0.0027	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—SMO—meningioma	1.25e-05	0.00269	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—PGR—meningioma	1.22e-05	0.00262	CbGpPWpGaD
Clenbuterol—TNF—MAPK Signaling Pathway—AKT1—meningioma	1.17e-05	0.00253	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—ALAD—meningioma	1.07e-05	0.0023	CbGpPWpGaD
Clenbuterol—TNF—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	1.06e-05	0.00228	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—ERBB2—meningioma	1.01e-05	0.00217	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—ERBB2—meningioma	9.21e-06	0.00198	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—TSHB—meningioma	8.85e-06	0.00191	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—TSHB—meningioma	8.66e-06	0.00187	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—HES1—meningioma	8.31e-06	0.00179	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—PTEN—meningioma	7.85e-06	0.00169	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—SMO—meningioma	7.53e-06	0.00162	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—SMO—meningioma	7.36e-06	0.00159	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—PGR—meningioma	7.22e-06	0.00156	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—PDGFB—meningioma	7.11e-06	0.00153	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—PGR—meningioma	7.06e-06	0.00152	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—TSHB—meningioma	6.89e-06	0.00148	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—ALAD—meningioma	6.82e-06	0.00147	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—TP53—meningioma	5.36e-06	0.00116	CbGpPWpGaD
Clenbuterol—TNF—Developmental Biology—AKT1—meningioma	4.96e-06	0.00107	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—HES1—meningioma	4.93e-06	0.00106	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—HES1—meningioma	4.83e-06	0.00104	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—ERBB2—meningioma	4.76e-06	0.00103	CbGpPWpGaD
Clenbuterol—NGF—Signaling Pathways—AKT1—meningioma	4.53e-06	0.000975	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—TSHB—meningioma	4.39e-06	0.000947	CbGpPWpGaD
Clenbuterol—ADRB3—GPCR downstream signaling—AKT1—meningioma	4.37e-06	0.000941	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—PDGFB—meningioma	4.22e-06	0.000909	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—meningioma	4.22e-06	0.000908	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—PDGFB—meningioma	4.13e-06	0.000889	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—PTEN—meningioma	4.06e-06	0.000876	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling by GPCR—AKT1—meningioma	3.96e-06	0.000854	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—ERBB2—meningioma	2.83e-06	0.000609	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—TP53—meningioma	2.77e-06	0.000598	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—ERBB2—meningioma	2.77e-06	0.000596	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—meningioma	2.69e-06	0.000579	CbGpPWpGaD
Clenbuterol—ADRB1—GPCR downstream signaling—AKT1—meningioma	2.59e-06	0.000558	CbGpPWpGaD
Clenbuterol—ADRB2—GPCR downstream signaling—AKT1—meningioma	2.53e-06	0.000546	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—PTEN—meningioma	2.41e-06	0.00052	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—PTEN—meningioma	2.36e-06	0.000508	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling by GPCR—AKT1—meningioma	2.35e-06	0.000507	CbGpPWpGaD
Clenbuterol—ADRB3—Signaling Pathways—AKT1—meningioma	2.34e-06	0.000505	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling by GPCR—AKT1—meningioma	2.3e-06	0.000496	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—PTEN—meningioma	1.88e-06	0.000405	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—TP53—meningioma	1.65e-06	0.000355	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—TP53—meningioma	1.61e-06	0.000347	CbGpPWpGaD
Clenbuterol—ADRB1—Signaling Pathways—AKT1—meningioma	1.39e-06	0.0003	CbGpPWpGaD
Clenbuterol—ADRB2—Signaling Pathways—AKT1—meningioma	1.36e-06	0.000293	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—PTEN—meningioma	1.2e-06	0.000258	CbGpPWpGaD
Clenbuterol—CYP1A1—Metabolism—AKT1—meningioma	1.08e-06	0.000233	CbGpPWpGaD
Clenbuterol—CYP1A2—Metabolism—AKT1—meningioma	6.9e-07	0.000149	CbGpPWpGaD
